ScriptPro has announced that its unique real time 340B processing system has successfully passed an intensive audit performed at University of Kentucky by Visante Inc. Visante is a leading firm in 340B audit and compliance support and is completely independent with no fiduciary relationship to ScriptPro or any other split-billing vendors. The audit covered over 100,000 prescriptions processed in UK pharmacies during the first half of 2016. According to Gary Johnson, Chief Pharmacy Officer of UK, “The audit confirms what we already knew. We can rely on the accuracy of ScriptPro’s real time processing system to ensure compliance with complex 340B regulations.” 

Jim Jorgenson, Chief Executive Officer of Visante, commends ScriptPro saying, “Visante congratulates ScriptPro for recognizing the critical value of the 340B Drug Pricing Program and for the decision to have its system evaluated by external, independent consultants.” The audit report concludes, “Visante feels confident that with continued focus on the 340B Program, and with the support of covered entity partners, ScriptPro will continue to provide a successful and compliant software solution to UK and other customers.” 

ScriptPro’s real time 340B compliance engine differs from after-the fact-processing methods used by other split-billing systems. According to Mike Coughlin, ScriptPro’s President and CEO, “Our 340B determinations are made by the pharmacy management system as prescriptions are filled. The system can then automatically direct staff to use 340B drug stock for qualified prescriptions. And it provides a basis for direct verification of prescription transactions rather than through analysis of aggregate data accumulations.” 

Johnson concurs with the importance of a transaction based approach. He says, “As stated in the Visante report, ScriptPro goes beyond the capabilities of other split-billing vendors when its qualifying logic can extend to considering the locations where prescriptions are written. This supports both flexibility and accuracy in qualifying prescriptions for 340B.”

Advertisement